CD59 Overview
Molecule Name
CD59 glycoprotein
Synonyms
CD59,16.3A5,1F5,EJ16,EJ30,EL32,FLJ38134,FLJ92039,G344,HRF20,MAC-IP,MACIF,MEM43,MGC2354,MIC11,MIN1,MIN2,MIN3,MIRL,MSK21,p18-20,Protectin
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
CD59 Antigens，Membrane attack complex inhibition factor，Membrane inhibitor of reactive lysis，MEM43 antigen，HRF-20，MIRL，20 kDa homologous restriction factor，MAC-inhibitory protein，MACIF，Protectin，MAC-IP，1F5 antigen，P18-20，CD59 Molecule， Complement Regulatory Protein，MSK21，CD59 Antigen， Complement Regulatory Protein，16.3A5，Lymphocytic Antigen CD59/MEM43，MIC11，MIN1，Ly-6-Like Protein，1F5，T Cell-Activating Protein，CD59 Antigen，EJ30，MIN2，MIN3，EL32，Surface Anitgen Recognized By Monoclonal Antibody 16.3A5，MEM43，EJ16，G344，CD59 Molecule (CD59 Blood Group)，Membrane Attack Complex (MAC) Inhibition Factor，CD59 Molecule，CD59 Antigen P18-20 (Antigen Identified By Monoclonal Antibodies 16.3A5， EJ16， EJ30， EL32 And G344)，Human Leukocyte Antigen MIC11，HRF20，CD59 Blood Group Antigen
Background
CD59, also known as membrane attack complex inhibition factor (MACIF), Protectin, 1F5 antigen, HRF-20 and MIRL. CD59 has been identified as a glycosylphosphatidylinositol-anchored membrane protein that acts as an inhibitor of the formation of the membrane attack complex to regulate complement activation. Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
CD59 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Onzemipgene Parvec | HMR-59; AAVCAGsCD59; JNJ-81201887; JNJ-1887 | Phase 2 Clinical | Tufts University | Geographic Atrophy; Macular Degeneration; Pyruvate kinase deficiency | Details |